612 related articles for article (PubMed ID: 34235598)
1. Lipoprotein (a): When to Measure and How to Treat?
Rhainds D; Brodeur MR; Tardif JC
Curr Atheroscler Rep; 2021 Jul; 23(9):51. PubMed ID: 34235598
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein(a).
Kronenberg F
Handb Exp Pharmacol; 2022; 270():201-232. PubMed ID: 34196811
[TBL] [Abstract][Full Text] [Related]
3. Is Lipoprotein(a) Clinically Actionable with Today's Evidence? The Answer is Yes.
Ma GS; Chiou TT; Wilkinson MJ
Curr Cardiol Rep; 2023 Oct; 25(10):1175-1187. PubMed ID: 37632608
[TBL] [Abstract][Full Text] [Related]
4. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
Vogt A
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
[TBL] [Abstract][Full Text] [Related]
5. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner Ž
Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.
Vinci P; Di Girolamo FG; Panizon E; Tosoni LM; Cerrato C; Pellicori F; Altamura N; Pirulli A; Zaccari M; Biasinutto C; Roni C; Fiotti N; Schincariol P; Mangogna A; Biolo G
Int J Environ Res Public Health; 2023 Sep; 20(18):. PubMed ID: 37754581
[TBL] [Abstract][Full Text] [Related]
7. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
8. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
Boffa MB
Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
[TBL] [Abstract][Full Text] [Related]
9. Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies.
Handhle A; Viljoen A; Wierzbicki AS
Vasc Health Risk Manag; 2021; 17():527-542. PubMed ID: 34526771
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a): the revenant.
Gencer B; Kronenberg F; Stroes ES; Mach F
Eur Heart J; 2017 May; 38(20):1553-1560. PubMed ID: 28329241
[TBL] [Abstract][Full Text] [Related]
12. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
Duarte Lau F; Giugliano RP
JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
[TBL] [Abstract][Full Text] [Related]
14. Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA).
Chiesa G; Zenti MG; Baragetti A; Barbagallo CM; Borghi C; Colivicchi F; Maggioni AP; Noto D; Pirro M; Rivellese AA; Sampietro T; Sbrana F; Arca M; Averna M; Catapano AL
Nutr Metab Cardiovasc Dis; 2023 Oct; 33(10):1866-1877. PubMed ID: 37586921
[TBL] [Abstract][Full Text] [Related]
15. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
16. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
Hung MY; Tsimikas S
Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
[TBL] [Abstract][Full Text] [Related]
17. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Banach M
Prog Cardiovasc Dis; 2020; 63(3):219-227. PubMed ID: 32277995
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
19. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk.
Melita H; Manolis AA; Manolis TA; Manolis AS
J Cardiovasc Pharmacol; 2022 Jan; 79(1):e18-e35. PubMed ID: 34694242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
